|
Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation |
Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H, Stevens J |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H, Stevens J. Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation. Health Technology Assessment 2012; 16(37): 1-253 Indexing Status Subject indexing assigned by NLM MeSH Antibodies, Monoclonal, Murine-Derived /economics /therapeutic use; Antineoplastic Agents /economics /therapeutic use; Antineoplastic Combined Chemotherapy Protocols /administration & Chlorambucil /administration & Cost-Benefit Analysis; Cyclophosphamide /administration & Doxorubicin /administration & England /epidemiology; Female; Humans; Lymphoma, Follicular /diagnosis /drug therapy /epidemiology /pathology; Male; Middle Aged; Mitoxantrone /administration & Models, Economic; Prednisolone /administration & Prednisone /administration & Randomized Controlled Trials as Topic; Rituximab; Vincristine /administration & Wales /epidemiology; dosage; dosage; dosage; dosage; dosage; dosage; dosage; dosage /therapeutic use AccessionNumber 22013006241 Date bibliographic record published 18/02/2013 |
|
|
|